At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 419 enrolled
Drug / intervention
BIIB033 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
In Brief
A Phase 2 clinical trial evaluating BIIB033, Placebo, and 1 other intervention for Multiple Sclerosis. Completed, enrolled 419 participants across 72 sites in 12 countries.
Detailed Summary
The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population pharmacokinetics of BIIB033 when used concurrently with Avonex.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesCanada, Czechia, France, Hungary, Italy, Netherlands, Poland, Russia, Serbia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartAug 2013
Primary CompletionDec 2015
Study CompletionMar 2016
TodayJul 2026
First PostedMay 29, 2013
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2015
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.1 years ago
Interventions
BIIB033drug
Placeboother
Avonexdrug